🇺🇸 FDA
Patent

US 11911484

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

granted A61KA61K47/60A61K47/6807

Quick answer

US patent 11911484 (Muscle targeting complexes and uses thereof for treating myotonic dystrophy) held by Dyne Therapeutics, Inc. expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K47/60, A61K47/6807, A61K47/6849, A61K47/6889